Contribute Try STAT+ Today

The Trump administration announced a new voluntary program that would lower the out-of-pocket cost Medicare beneficiaries pay for insulin to $35 a month, a move designed to deflate rising anger over prices for medicines and, consequently, give President Trump a lift during an election year.

Assuming drug makers and insurers participate, people with diabetes who enroll in a participating Medicare Part D plan are forecast to save an average of $446 annually, or more than 66% of what they pay today, according to the Centers for Medicare and  Medicaid Services. CMS believes that more than 3.3 million Medicare beneficiaries receive one or more of the common forms of insulin.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy